

This document is an English-translated version of an attachment of notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Finerenone

June 11, 2024

Therapeutic category

Other cardiovascular agents

Non-proprietary name

Finerenone

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision												
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Itraconazole, preparations containing ritonavir, atazanavir, darunavir, fosamprenavir, preparations containing cobicistat, clarithromycin, ensitrelvir</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Itraconazole, <u>posaconazole, voriconazole</u>, preparations containing ritonavir, atazanavir, darunavir, fosamprenavir, preparations containing cobicistat, clarithromycin, ensitrelvir</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>												
<table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td>Itraconazole Preparations containing ritonavir Atazanavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir</td><td>The blood concentration of finerenone may increase markedly.</td><td>The clearance of finerenone is decreased by the potent inhibition of CYP3A.</td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Itraconazole Preparations containing ritonavir Atazanavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir	The blood concentration of finerenone may increase markedly.	The clearance of finerenone is decreased by the potent inhibition of CYP3A.	<table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td>Itraconazole <u>Posaconazole</u> <u>Voriconazole</u> Preparations containing ritonavir Atazanavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir</td><td>The blood concentration of finerenone may increase markedly.</td><td>The clearance of finerenone is decreased by the potent inhibition of CYP3A.</td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Itraconazole <u>Posaconazole</u> <u>Voriconazole</u> Preparations containing ritonavir Atazanavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir	The blood concentration of finerenone may increase markedly.	The clearance of finerenone is decreased by the potent inhibition of CYP3A.
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Itraconazole Preparations containing ritonavir Atazanavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir	The blood concentration of finerenone may increase markedly.	The clearance of finerenone is decreased by the potent inhibition of CYP3A.											
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Itraconazole <u>Posaconazole</u> <u>Voriconazole</u> Preparations containing ritonavir Atazanavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir	The blood concentration of finerenone may increase markedly.	The clearance of finerenone is decreased by the potent inhibition of CYP3A.											